Sharp Shalini 4
4 · NEUROCRINE BIOSCIENCES INC · Filed May 21, 2024
Insider Transaction Report
Form 4
Sharp Shalini
Director
Transactions
- Exercise/Conversion
Common Stock
2024-05-17+2,100→ 2,100 total - Sale
Common Stock
2024-05-17$141.90/sh−1,106$156,943→ 994 total - Exercise/Conversion
Restricted Stock Unit
2024-05-17−2,100→ 0 total→ Common Stock (2,100 underlying)
Footnotes (4)
- [F1]The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- [F2]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $140.81 to $142.33. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range
- [F3]Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.
- [F4]This RSU award was granted to the Reporting Person on May 17, 2023 and is fully vested.